3β-(4-Methoxybenzyloxy)pregn-5-en-20-one for Selective CB1 Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological treatments for Cannabinoids-Related Disorders, such as those induced by THC, suffer from adverse effects like reduced food intake, anxiety, depression, glucocorticoid secretion, withdrawal symptoms, convulsions, and hepatotoxicity, and lack specificity in inhibiting CB1 receptor activity.
Innovation Solution
A specific pregnenolone derivative, 3β-(4-methoxybenzyloxy)pregn-5-en-20-one, selectively inhibits CB1 receptor signaling without affecting basal activity, transforming THC into a cAMP-biased agonist, thereby reducing the unconditioned and conditioned behavioral effects of THC without causing adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If orthosteric CB1 antagonists (e.g., rimonabant) are used to block CB1 receptor activity, then the therapeutic effect on Cannabinoids-Related Disorders is improved, but severe adverse effects occur including reduced food intake, anxiety, depression, glucocorticoid secretion, withdrawal symptoms, convulsions, and hepatotoxicity
Solution Approach 1:
The invention segments the CB1 receptor signaling pathways by developing a compound that selectively inhibits only the pathological signaling pathways (such as MAPK pathway activation) while leaving physiological pathways (such as cAMP pathway) intact. This selective inhibition approach divides the receptor's functions into treatable and protected components, resolving the contradiction between therapeutic efficacy and adverse effects.
Solution Approach 2:
The compound exhibits local quality by demonstrating signaling-specific inhibition where different parts of the CB1 receptor signaling network are differentially affected. The inhibition is localized to specific pathological pathways rather than globally affecting all CB1 receptor functions, thereby achieving therapeutic effect without the broad-spectrum adverse effects of traditional antagonists.
2Object-affected harmful factors
If traditional CB1 antagonists inhibit the entire activity of the CB1 receptor including basal activity, then the receptor's pathological activation is blocked, but the basal activity necessary for normal physiological function is also suppressed
Solution Approach 1:
The compound applies partial action by selectively inhibiting only the excessive or pathological activation of CB1 receptor signaling pathways while allowing basal and physiological activities to continue uninterrupted. This partial inhibition strategy targets only the harmful excess activation without suppressing the necessary baseline function of the receptor.
Solution Approach 2:
The invention changes the parameter of receptor inhibition from global to selective by modifying how the compound interacts with different signaling pathways. The compound alters the activation state of specific pathways (inhibiting pathological ones) while maintaining others (physiological ones), effectively changing the inhibition parameter from binary (on/off) to selective (pathway-specific).
Data Source
AI summary
The present invention generally relates to a specific pregnenolone derivative for its use for the treatment of a Cannabinoids-Related Disorder. More particularly, the invention relates to a compound of Formula (I)for its use in the treatment of a Cannabinoids-Related Disorder. Indeed, the compound of the invention is in vivo very potent in inhibiting the effects of THC, and is able to inhibit both unconditioned and conditioned effects of THC including THC self-administration and reinstatement in THC seeking in non-human primates.